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Abstract
Background: Owing to advances in the critical care of premature infants with bronchopulmonary dysplasia (BPD),
BPD-associated pulmonary hypertension (PH) is becoming a growing concern. However, only few investigations
were available on neurodevelopmental outcomes in preterm infants with PH. Therefore, this study aimed to identify
the impact of PH on growth and neurodevelopment at 18–24 months of corrected age (CA).
Methods: We retrospectively analyzed the medical records of 394 infants (aged < 28 weeks of gestation) admitted
to the neonatal intensive care unit between 2005 and 2014. Among the surviving infants, 123 returned for follow-
up evaluations including the Bayley Scales of Infant and Toddler Development, third Edition (Bayley-III) screening tests
and growth assessment at 18–24 months of CA. Among the 81 infants with moderate or severe BPD, 20 met the
criteria for PH. Baseline characteristics and outcomes were compared in infants who developed BPD-associated PH
(PH group, n = 20) and moderate or severe BPD infants who did not develop PH (non-PH group, n = 61).
Results: Compared to the non-PH group, the PH group showed significantly lower cognitive (85 vs. 95, p = 0.004),
language (81 vs. 89, p = 0.040), and motor (88 vs. 94, p = 0.010) scores of the Bayley-III at 18–24 months of CA.
Cognitive delay was found in 45.0% (9/20) of PH infants. In addition, z-scores of weight (− 1.4 ± 1.3 vs. -0.6 ± 1.1%,
p = 0.011) and HC (− 1.2 ± 1.8 vs. 0.53 ± 1.0%, p = 0.035) were significantly lower in the BPD with PH group. With the
subgroup analysis in infants with severe BPD only, the cognitive score was consistently lower and poorer and
weight gain after discharge was identified in infants with PH and severe BPD.
Conclusion: PH was a worsening factor of non-optimal growth and poor neurodevelopmental outcome in preterm
infants with BPD at 18–24 months of CA. Our findings suggest the importance of close developmental follow-up
and recognition of that risk to help optimize the outcome of preterm infants with PH.
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Background
Improved critical care management of premature infants
has led to an increased survival rate of patients with
bronchopulmonary dysplasia (BPD), which is the leading
cause of late respiratory morbidity in preterm infants [1].
Early injury of the developing lung impairs angiogenesis
and alveolarization, which in turn contributes to the devel-
opment of BPD and BPD-associated pulmonary hyperten-
sion (PH). PH is a significant cardiovascular complication
in infants with BPD and is associated with increased mor-
bidity and mortality, such as longer hospitalization and
oxygen therapy [2–4]. Recent efforts to identify PH in in-
fants with BPD using echocardiography have shown that
this modality may provide an opportunity for implementa-
tion of preventive or treatment strategies to improve
long-term outcomes [5]. Despite the increased concern for
PH, long-term outcomes in infants with BPD-associated
PH remain unclear. Recently, several studies have reported
cardiovascular outcomes of PH in preterm infants;
however, no large longitudinal study that reported
long-term pulmonary or neurodevelopmental outcomes in
these infants is currently available [6, 7].
Since the association between BPD and poor neurodeve-
lopment has already been established, children with BPD
have higher rates of cognitive, educational, and behavioral
impairments [8, 9]. However, with diverse interactions
known to occur between prenatal and postnatal factors, the
influence of PH in BPD on growth and neurodevelopmental
outcomes has not been well established [4, 10–12]. Recently,
Nakanishi et al. suggested in a current retrospective study
that BPD with PH is a possible independent risk factor for
neurodevelopmental impairment at 3 years of age [13].
The aim of the present study was to determine
somatic growth and developmental outcomes in infants
with BPD-associated PH at 18–24 months of corrected
age (CA), highlighting their differences from infants with
BPD, but without PH.
Methods
Study population
We retrospectively reviewed medical records of 394 pre-
term infants who were born at < 28 weeks’ gestational
age and were admitted to the neonatal intensive care
unit of Seoul National University Children’s Hospital
between January 2005 and December 2014. Infants with
major congenital anomalies, chromosomal abnormal-
ities, and incomplete medical records were excluded.
Additional exclusion criteria were missing neurodevelop-
mental assessment and growth data at 18–24months of
CA and severe neurological injury.
Data collection and definitions
The following clinical data of infants were collected:
birth weight, gestational age, small for gestational age
(SGA; birth weight < 10th percentile for age according to
Fenton growth charts), prenatal steroids (administration
of any dose of corticosteroids during the concurrent
pregnancy), histological chorioamnionitis (histopatho-
logical evidence of the presence of acute inflammatory
changes in membrane roll and placental chorionic plate),
and oligohydramnios (amniotic fluid index < 5 cm de-
tected by ultrasonography performed just before deliv-
ery). The comorbidities of preterm infants were also
assessed, such as respiratory distress syndrome (RDS;
the presence of respiratory distress, increased oxygen
requirement, and radiological findings consistent with
RDS), patent ductus arteriosus (PDA) and its treatment,
intraventricular hemorrhage (IVH; grading according to
Papile’s classification [14]), culture-proven sepsis (deter-
mined at least in a single positive blood culture, and
clinical signs of infection), retinopathy of prematurity,
and necrotizing enterocolitis (NEC; according to modi-
fied Bell’s criteria [15]). BPD was defined as per the
National Institute of Health consensus definition and
graded as mild, moderate, or severe, according to the
fraction of inspired oxygen (FiO2) or positive pressure
ventilation (PPV) [16]. Mild BPD was defined as breathing
room air, moderate BPD was defined as FiO2 of < 0.30,
and severe BPD was defined as FiO2 of ≥0.30 or PPV at
36 weeks’ post-menstrual age. Patients with PDA were
treated with cyclooxygenase inhibitors or surgical ligation.
The following factors were used to estimate short-term
respiratory prognosis: postnatal steroid use, duration of
mechanical ventilation, home oxygen therapy, and total
amount of oxygen supplementation until 36 weeks’ post-
menstrual age calculated as supplemented extra oxygen
concentration [%] (fraction of inspired oxygen – 21) ×
duration [h] [17]. The episodes of hypoxemia (defined as
single or consecutive values of SpO2, < 80%) and bradycar-
dia (pulse rate, < 80 /min) not recovering spontaneously
were reviewed until 36 weeks’ post-menstrual age or
discharge in infants with severe BPD.
Pulmonary hypertension
Monthly echocardiographic examinations of preterm in-
fants with BPD were conducted to screen for PH. Serial
echocardiographic data of all preterm infants with BPD
were reviewed, including two-dimensional, M-mode, and
color-coded Doppler evaluation performed by a pediatric
cardiologist at Seoul National University Children’s
Hospital. Infants were diagnosed with PH if an echocar-
diogram performed at age older than 2months demon-
strated elevated pulmonary artery pressure based on the
presence of at least one of the following criteria: 1) the
velocity of tricuspid valve regurgitation of ≥3 m/s in the
absence of pulmonary stenosis or 2) flat or left-deviated
interventricular septal configuration and right ventricu-
lar hypertrophy with chamber dilation [18].
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Growth and neurodevelopmental assessment
Preterm infants discharged home were evaluated at 18–
24months of CA by one neonatologist in the neonat-
ology outpatient clinic. Assessments included composite
scores on the Bayley Scales of Infant and Toddler Develop-
ment, third edition (Bayley-III) [19], and growth parame-
ters (body weight, head circumference [HC], and length).
Cognitive, language, and motor delay was defined as a
composite score of < 85 [one standard deviation (SD)
below the mean of 100] on the Bayley-III. Growth data
were presented as z-scores, because infants were assessed
at different gestational ages at birth and approximately at
18–24months of CA. Fenton preterm growth charts were
used as reference values from 22 to 50 gestational weeks,
and the World Health Organization (WHO) Anthro
software (WHO, Geneva, Switzerland) was used from
term age onward. According to the WHO growth defin-
ition, underweight was defined as a z-score of ≤2.0.
Statistical analysis
Data analysis was performed using SPSS 20.0 for Win-
dows (SPSS Inc., Chicago, IL, USA). Continuous variables
were analyzed using either the t-test or the Mann-Whit-
ney U-test for normal or skewed distributions.
Proportions were tested using chi-squared test and Fish-
er’s exact test. P-values of < 0.05 were considered statisti-
cally significant. Data were presented as mean ± SD,
median and range, or rate.
Results
Of the 394 preterm infants born before 28 weeks of
gestation, 6 were excluded due to major congenital mal-
formations and chromosomal anomalies and 72 died
before discharge or had incomplete data (Fig. 1). A total
of 60 infants with grade III or IV IVH, periventricular
leukomalacia, cerebral infarction, or hypoxic ischemic
encephalomalacia diagnosed by cranial ultrasound or
brain MRI were excluded to control for neurologic com-
plications. Among the surviving infants, 123/256 (48.0%)
returned for follow-up evaluations at 18–24months of
CA. In 123 preterm infants, 81 (66%) were classified
with severe (40 of 81 infants) or moderate (41 of 81
infants) BPD. PH was diagnosed in 43% (17/40) of in-
fants with severe BPD, 7% (3/41) of infants with moder-
ate BPD, and 0% (0/42) of infants with no or mild BPD.
Among the 81 infants with moderate or severe BPD, 20
(25%) met the criteria for PH. A flow chart showing the
study design is presented in Fig. 1.
Fig. 1 Flow chart of the study population
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Clinical characteristics and short-term morbidities of in-
fants with and without PH are presented in Table 1. No
difference was observed in gestational age (p = 0.126),
antenatal steroid exposure (p = 0.601), or post-natal
steroid exposure (p = 0.128) for infants affected by BPD
with PH compared to those affected by BPD without PH.
Severe BPD was more prevalent in the PH group than in
the non-PH group (85% vs. 15%, p < 0.001). Fifty-five per-
cent of infants with PH had a history of culture proven
sepsis, which was significantly higher than the number of
infants without PH (p = 0.011). The median duration of
hospitalization was longer in the PH group when com-
pared to the non-PH group (p = 0.044). Table 2 shows the
growth and developmental outcomes of infants with and
without PH and BPD at 18–24months of CA. Mean
z-scores of weight (− 1.4 ± 1.3 vs. -0.6 ± 1.1%, p = 0.011)
and HC (− 1.2 ± 1.8 vs. 0.53 ± 1.0%, p = 0.035) were signifi-
cantly lower in the BPD with PH group than in the
non-PH. In addition, the BPD with PH group showed
significantly lower scores than the non-PH group in the
cognitive (85 vs. 95, respectively, p = 0.004), language (81
vs. 89, p = 0.040), and motor (88 vs. 94, p = 0.010) areas of
the Bayley-III. The prevalence of cognitive delay (45.0% vs.
9.8%, p < 0.001) was significantly higher in the BPD with
PH group than those in the non-PH group.
Table 3 shows the clinical characteristics according to
the presence or absence of PH only in infants with
severe BPD, which allowed to clarify the effects of PH.
Among the infants with severe BPD, the clinical charac-
teristics were statistically and significantly different
between the infants with PH and those without PH in
one variable: multiple births (17.6% vs. 60.9%, p = 0.010).
The duration of mechanical ventilation (p = 0.090), the
rate of infants who received dexamethasone rescue ther-
apy (p = 1.000), the total amount of oxygen supplemen-
tation until 36 weeks’ postmenstrual age (p = 0.434), and
the episodes of hypoxemia or bradycardia (p = 0.254 and
p = 0.734, respectively) were not significantly different in
the two groups. Table 4 shows the growth and develop-
mental outcomes of infants with and without PH and
severe BPD. At hospital discharge, no difference was
found between the two groups according to the z-scores
of the body weight and HC. However, at 18–24months
of CA, the mean z-score of body weight was significantly
lower in infants with PH than in those without (− 1.7 ±
1.2 vs. -0.7 ± 1.3, p = 0.016). Compared to infants without
PH, those with PH had lower cognitive scores (85 vs. 95,
p = 0.048) only in Bayley-III.
Discussion
This study found that the infant survivors with
BPD-associated PH have significantly lower cognitive,
language, and motor composite scores in the Bayley-III
at 18–24months of CA. In addition, the number of in-
fants with cognitive delay was significantly higher in the
BPD with PH group. Infants with BPD-associated PH
Table 1 Clinical characteristics of subjects with and without
pulmonary hypertension in infants with moderate/severe BPD
PH Non-PH P-values
(n = 20) (n = 61)
Gestational age, weeks 25.3 ± 1.4 25.8 ± 1.1 0.126
Birth weight, g 710.1 ± 183.6 758.6 ± 159.1 0.257
Birth weight < 10th
percentile for age, n (%)
5 (25.0) 9 (14.8) 0.317
Multiple birth, n (%) 3 (15.0) 35 (57.4) 0.002
Cesarean section, n (%) 13 (65.0) 35 (57.4) 0.608
Perinatal steroids
administration, n (%)
15 (75.0) 42 (68.9) 0.601
Chorioamnionitis, n (%) 12 (60.0) 25 (41.0) 0.138
Preeclampsia, n (%) 3 (15.0) 6 (9.8) 0.750
Oligohydramnios, n (%) 4 (20.0) 3 (5.1) 0.059
RDS, n (%) 16 (80.0) 45 (73.8) 0.767
Treated PDA, n (%) 16 (80.0) 47 (77.0) 1.000
BPD, n (%) < 0.001
Moderate 3 (15.0) 38 (62.3)
Severe 17 (85.0) 23 (37.7)
Culture proven sepsis, n (%) 11 (55.0) 15 (24.6) 0.011
ROP operation, n (%) 7 (35.0) 34 (55.7) 0.128
NEC operation, n (%) 6 (30.0) 6 (9.8) 0.063
BPD steroid, n (%) 5 (25.0) 6 (9.8) 0.128
Length of stay, days 111 (82–268) 103 (71–163) 0.044
Data are presented as mean ± SD, median and range, or rate
PH pulmonary hypertension, RDS respiratory distress syndrome, PDA patent
ductus arteriosus, BPD bronchopulmonary dysplasia, ROP retinopathy of
prematurity, NEC necrotizing enterocolitis
Table 2 Growth and developmental outcomes of infants with
or without pulmonary hypertension (PH) and moderate/severe
bronchopulmonary dysplasia (BPD)
PH Non-PH P-values
(n = 20) (n = 61)
Growth at 18–24months
Body weight, kg 9.5 ± 1.5 10.2 ± 1.3 0.051
z-score −1.4 ± 1.3 −0.6 ± 1.1 0.011
Head circumference, cm 44.9 ± 1.9 46.4 ± 1.5 0.001
z-score −1.2 ± 1.8 −0.53 ± 1.0 0.035
Bayley-III at 18–24 months
Cognitive score 85 (65–105) 95 (55–125) 0.004
Score < 85 9 (45.0) 6 (9.8) < 0.001
Language score 81 (47–100) 89 (53–118) 0.040
Score < 85 10 (50.0) 20 (32.8) 0.167
Motor score 88 (52–107) 94 (46–115) 0.010
Score < 85 8 (40.0) 12 (20.3) 0.081
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had much lower body weights and HC than those with
BPD only. Moreover, after adjusting for BPD severity,
cognitive scores and body weight particularly remained
lower in infants with PH and severe BPD. Recently,
Nakanishi et al. [13] also reported that the developmen-
tal quotient (DQ) of < 70 in all areas using Kyoto Scale
of Psychological Development (KSPD) was more preva-
lent and the body weight was lower than that in the
non-PH group in 3-year-old infants with BPD-associated
PH. However, no significant differences were detected in
postural-motor, cognitive-adaptive, or language-social
domain scores. In the present study, we found that not
only a prevalence of cognitive score of < 85 was signifi-
cantly higher but also the means of scores in cognitive,
language, and motor areas were significantly lower in
PH with moderate/severe BPD group, according to the
Bayley-III scales, a global standard assessment method
for preterm-born infants.
The severity of BPD has been recognized to be associ-
ated with poor neurodevelopmental outcomes. The
mechanism may include multifactorial pathophysiology
such as chronic, intermittent hypoxia associated with
prolonged oxygen dependence leading to hypoxic-ische-
mic cerebral injury [20]. PH may exacerbate these com-
plications because of hemodynamic instability and
severe hypoxemia. In the present study, despite the fact
that infants with BPD and PH had lower cognitive scores
compared to those without PH, respiratory management,
such as total extra oxygen supplementation, intermittent
hypoxemia, and bradycardia events, was not different
between the two groups. Although one study by Lodha
et al. [21] showing that BPD with chronic oxygen
Table 3 Clinical characteristics according to the presence or absence of PH in severe BPD
Severe BPD
PH Non-PH P-values
(n = 17) (n = 23)
Gestational age, weeks 25.3 ± 1.4 25.5 ± 1.0 0.470
Birth weight, g 709.5 ± 195.5 744.0 ± 158.6 0.543
Birth weight < 10th percentile for age, n (%) 5 (29.4) 4 (17.4) 0.456
Multiple birth, n (%) 3 (17.6) 14 (60.9) 0.010
Cesarean section, n (%) 12 (70.6) 13 (56.5) 0.512
Perinatal steroids administration, n (%) 13 (76.5) 17 (77.3) 1.000
Chorioamnionitis, n (%) 9 (52.9) 11 (47.8) 0.749
Preeclampsia, n (%) 3 (18.8) 2 (8.7) 0.631
Oligohydramnios, n (%) 4 (23.5) 2 (8.7) 0.373
RDS, n (%) 14 (82.4) 19 (82.6) 1.000
Treated PDA, n (%) 14 (82.4) 18 (78.3) 0.616
Culture proven sepsis, n (%) 9 (52.9) 8 (34.8) 0.251
ROP operation, n (%) 6 (35.3) 14 (60.9) 0.110
NEC operation, n (%) 5 (31.2) 3 (13.0) 0.235
Length of stay, days 115 (94–268) 113 (77–163) 0.448
Respiratory management
Duration of CV or HFV, days 72 (0–199) 40 (6–148) 0.090
BPD steroid, n (%) 5 (29.4) 6 (26.1) 1.000
Dexamethasone cumulative dose (mg/kg) 1.80 (1.10–3.23) 1.10 (0.42–3.04) 0.416
Discharge on oxygen, n (%) 12 (70.6) 15 (65.2) 0.720
Total extra O2 supplementation
a 25,199 (1428–71,095) 20,325 (11,417–46,362) 0.434
Episodes of hypoxiab 338 (172–1205) 258 (57–696) 0.254
Episodes of bradycardiac 40 (8–216) 56 (4–169) 0.734
Data are presented as mean ± SD, median and range, or rate
PH pulmonary hypertension, BPD bronchopulmonary dysplasia, RDS respiratory distress syndrome, PDA patent ductus arteriosus, ROP retinopathy of prematurity,
NEC necrotizing enterocolitis, CV conventional ventilation, HFV high-frequency ventilation
a Supplemented extra O2 concentration (%) (fraction of inspired O2− 21%)
b Single value or consecutive values of SpO2 < 80% until 36 weeks of postmenstrual age
c Single value or consecutive values of pulse rate < 80 /min until 36 weeks of postmenstrual age
Choi et al. BMC Pediatrics           (2019) 19:26 Page 5 of 8
dependency does not predict adverse neurodevelopmen-
tal outcomes compared to BPD only may support our
result, causative pathophysiology on poor neurological
outcomes by PH should be identified in a further study
because peripheral capillary oxygen saturation (SpO2)
and heart rate provide limited information on organ
perfusion and systemic blood flow [22]. The further bed-
side neuro-monitoring technique includes near-infrared
spectroscopy or amplitude-integrated electroencephalog-
raphy to detect events of decreased cerebral oxygenation
or changes in cortical activity could help to inform the
risk of brain injury. Early identification of preterm
infants at risk of neurologic injury by respiratory events
in infants with PH will enable to initiate the neuropro-
tective strategies.
We also found that the body weight and HC were
lower at 18–24months of CA in the PH compared to
non-PH group. Prenatal and postnatal restricted growth
can be a potential explanation of neurodevelopmental
disability. Placental insufficiency as manifested by SGA
has been recognized as an important risk factor for BPD
and PH [12]. Although the fact that SGA increases the
risk of adverse neurodevelopmental outcomes in prema-
ture infants remains controversial, some studies reported
increased levels of cognitive and behavioral difficulties in
infants with SGA [23]. Furthermore, the association
between postnatal growth failure and poorer neurodeve-
lopmental outcomes in preterm infants has been well
established in several large cohort studies [24, 25]. In the
present study, the prevalence of SGA was not signifi-
cantly different between the two groups, but poorer
weight gain after discharge was identified in infants with
PH and severe BPD compared to those with severe BPD
only. Several mechanisms of growth failure have been
proposed in infants with BPD: increased caloric expend-
iture in the work of breathing, restricted fluids, diuretic
and postnatal steroid therapy, and different comorbidi-
ties, such as sepsis [26]. PH can be a causative or wors-
ening factor especially in increasing caloric expenditure,
restricted fluid or diuretic therapy in infants with severe
BPD. The possible mechanism that PH causes failure of
growth should be elucidated in a future prospective
study.
In the total population analysis, the incidence of mod-
erate or severe BPD was significantly higher in the PH
group than that in the non-PH group. Because the BPD
severity per se is known as a major risk factor for
adverse neurological outcomes, the results in clinical
outcomes should be cautiously interpreted by clarifying
the effects of PH alone [8, 9, 13]. Therefore, a subgroup
analysis was conducted on infants with severe BPD only
to avoid the influence of GA, body weight, and mostly
BPD severity, which demonstrated several interesting
findings. The incidence of sepsis was significantly high
in the PH group in the total population analysis; how-
ever, our subgroup analysis according to BPD severity
showed that the two groups exhibited no difference in
clinical characteristics. Furthermore, the language and
motor outcomes were significantly lower in the PH
group in the total population analysis but such results
were not observed in the subgroup analysis. These
finding might reaffirm that BPD severity per se is a
major risk factor and many factors correlated with BPD
severity may intricately play a role on adverse neurode-
velopmental outcomes. The most notable point we
demonstrated in the subgroup analysis in this study is to
suggest that PH might be an additional risk factor for
cognitive impairment in infants with severe BPD. Al-
though other factors such as sepsis and NEC were not
found as significant additional risk factors, the role of
these factors cannot be concluded because of the retro-
spective design, small sample size, and low follow-up
rate at 18–24 months of CA in this study. Further pro-
spective large-scale studies might clarify the intricate
correlation of these factors on the adverse neurodevelop-
mental outcomes in infants with severe BPD and PH.
Conclusion
In summary, preterm infants with PH have shown
significantly low scores in cognitive, language, and motor
areas in the Bayley-III at 18–24months of CA. With
subgroup analysis in infants with severe BPD only, the
cognitive score remained low in infants with PH.
Furthermore, growth restriction is more likely to persist
after discharge in severe BPD infants with PH than in
Table 4 Growth and developmental outcomes of infants with
and without PH and with severe BPD
PH Non-PH P-values
(n = 17) (n = 23)
Growth at hospital discharge
Body weight, kg 3.4 ± 1.0 2.9 ± 0.6 0.098
z-score −2.2 ± 1.7 −2.1 ± 1.5 0.982
Head circumference, cm 33.7 ± 2.8 33.3 ± 1.8 0.663
z-score −2.3 ± 1.5 − 1.8 ± 1.0 0.225
Growth at 18–24months
Body weight, kg 9.2 ± 1.4 10.1 ± 1.3 0.050
z-score −1.7 ± 1.2 − 0.7 ± 1.3 0.016
Head circumference, cm 44.7 ± 2.0 46.0 ± 1.4 0.024
z-score − 1.3 ± 1.9 − 0.7 ± 1.1 0.243
Bayley-III at 18–24 months
Cognitive 85 (65–105) 95 (55–110) 0.048
Language 83 (47–100) 83 (53–115) 0.551
Motor 88 (52–97) 89 (46–110) 0.124
PH pulmonary hypertension, BPD bronchopulmonary dysplasia
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infants with severe BPD only. Therefore, a more tailored
approach on post-discharge neurodevelopment and
growth should be implemented for long-term follow-up
of preterm infants with BPD-associated PH. Additional
prospective and large studies are needed to confirm our
results and to provide information that improves the
long-term outcomes of preterm infants with PH.
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